Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling
Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was...
Gespeichert in:
Veröffentlicht in: | Drug metabolism and disposition 2009-04, Vol.37 (4), p.745-752 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 752 |
---|---|
container_issue | 4 |
container_start_page | 745 |
container_title | Drug metabolism and disposition |
container_volume | 37 |
creator | Shebley, Mohamad Kent, Ute M. Ballou, David P. Hollenberg, Paul F. |
description | Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was significantly affected as a result of the inactivation, whereas binding of the inhibitor n-octylamine, a type II ligand, was not compromised. Binding of these ligands to P450 2B6 occurs in two phases. Stopped-flow spectral analysis of the binding kinetics of benzphetamine to PCP-inactivated 2B6 revealed a 15-fold decrease in the rate of binding during the second phase of the kinetics (k1 = 5.0 s–1, A1 = 30%; k2 = 0.02 s–1, A2 = 70%, where A2 indicates the fractional magnitude of the second phase) compared with the native enzyme (k1 = 8.0 s–1, A1 = 58%; k2 = 0.3 s–1, A2 = 42%). Analysis of benzphetamine metabolism by the inactivated protein using liquid chromatography/electrospray ionization/mass spectrometry showed that the rates of formation of nor-benzphetamine and hydroxylated nor-benzphetamine were decreased by 75 and 69%, respectively, whereas the rates of formation for amphetamine, hydroxybenzphetamine, and methamphetamine showed slight but statistically insignificant decreases after the inactivation. The rate of reduction of P450 2B6 by NADPH and reductase was decreased by 6-fold as a result of the modification by PCP. In addition, the extent of uncoupling of NADPH oxidation from product formation, a process leading to futile production of H2O2, increased significantly during the metabolism of ethylbenzene as a result of the inactivation. |
doi_str_mv | 10.1124/dmd.108.024661 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2680542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009095562402004X</els_id><sourcerecordid>S009095562402004X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-85be7c3ababf1f30a7492e03a1686ca667bfec92e1bddba3f8666abcb4fd8f793</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxSMEokvhyhH5wq1Z7MRxEg5I7WoLlYqoRCtxs8b_NkaJvbK9W-Vj8I3ralctHDjNyO83z6N5RfGe4CUhFf2kJrUkuFviijJGXhQL0lSkxLj_9bJY5ILLvmnYSfEmxt8YE0rr_nVxQvrctS1eFH--azmAszFZic4djHO0EXmD0qDRlQOZ7B6S9e7xbTUnL4fgJ41uaINRdcGQmNHNoJ2c5WiVdfozWhujZcomDv3ciZgCJI0urMvq5gytxyyGrN0GcNHocIbAKXTnpN9tx4y8LV4ZGKN-d6ynxd3l-nb1rbz-8fVqdX5dStq3qewaoVtZgwBhiKkxtLSvNK6BsI5JYKwVeY38RIRSAmrTMcZASEGN6kzb16fFl4PvdicmraR2edORb4OdIMzcg-X_Ks4OfOP3vGIdbmiVDZYHAxl8jEGbp1mC-WM4PIeT-44fwskDH_7-8Rk_ppGBj0cAooTR5AtJG5-4ilQdbSr6zA12M9zboPl2gDCB9KPfzLxuOeUtbTLXHTid77i3OvAobc5KqzwjE1fe_m_XB0oUu5E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Shebley, Mohamad ; Kent, Ute M. ; Ballou, David P. ; Hollenberg, Paul F.</creator><creatorcontrib>Shebley, Mohamad ; Kent, Ute M. ; Ballou, David P. ; Hollenberg, Paul F.</creatorcontrib><description>Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was significantly affected as a result of the inactivation, whereas binding of the inhibitor n-octylamine, a type II ligand, was not compromised. Binding of these ligands to P450 2B6 occurs in two phases. Stopped-flow spectral analysis of the binding kinetics of benzphetamine to PCP-inactivated 2B6 revealed a 15-fold decrease in the rate of binding during the second phase of the kinetics (k1 = 5.0 s–1, A1 = 30%; k2 = 0.02 s–1, A2 = 70%, where A2 indicates the fractional magnitude of the second phase) compared with the native enzyme (k1 = 8.0 s–1, A1 = 58%; k2 = 0.3 s–1, A2 = 42%). Analysis of benzphetamine metabolism by the inactivated protein using liquid chromatography/electrospray ionization/mass spectrometry showed that the rates of formation of nor-benzphetamine and hydroxylated nor-benzphetamine were decreased by 75 and 69%, respectively, whereas the rates of formation for amphetamine, hydroxybenzphetamine, and methamphetamine showed slight but statistically insignificant decreases after the inactivation. The rate of reduction of P450 2B6 by NADPH and reductase was decreased by 6-fold as a result of the modification by PCP. In addition, the extent of uncoupling of NADPH oxidation from product formation, a process leading to futile production of H2O2, increased significantly during the metabolism of ethylbenzene as a result of the inactivation.</description><identifier>ISSN: 0090-9556</identifier><identifier>EISSN: 1521-009X</identifier><identifier>DOI: 10.1124/dmd.108.024661</identifier><identifier>PMID: 19144770</identifier><identifier>CODEN: DMDSAI</identifier><language>eng</language><publisher>Bethesda, MD: Elsevier Inc</publisher><subject>Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors ; Aryl Hydrocarbon Hydroxylases - metabolism ; Benzphetamine - pharmacokinetics ; Biological and medical sciences ; Catalysis ; Chromatography, Liquid ; Cytochrome P-450 CYP2B6 ; Electron Transport ; Enzyme Inhibitors - pharmacology ; Medical sciences ; Oxidoreductases, N-Demethylating - antagonists & inhibitors ; Oxidoreductases, N-Demethylating - metabolism ; Pharmacology. Drug treatments ; Phencyclidine - pharmacology ; Spectrometry, Mass, Electrospray Ionization ; Substrate Specificity</subject><ispartof>Drug metabolism and disposition, 2009-04, Vol.37 (4), p.745-752</ispartof><rights>2009 American Society for Pharmacology and Experimental Therapeutics</rights><rights>2009 INIST-CNRS</rights><rights>Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-85be7c3ababf1f30a7492e03a1686ca667bfec92e1bddba3f8666abcb4fd8f793</citedby><cites>FETCH-LOGICAL-c497t-85be7c3ababf1f30a7492e03a1686ca667bfec92e1bddba3f8666abcb4fd8f793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21284524$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19144770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shebley, Mohamad</creatorcontrib><creatorcontrib>Kent, Ute M.</creatorcontrib><creatorcontrib>Ballou, David P.</creatorcontrib><creatorcontrib>Hollenberg, Paul F.</creatorcontrib><title>Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling</title><title>Drug metabolism and disposition</title><addtitle>Drug Metab Dispos</addtitle><description>Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was significantly affected as a result of the inactivation, whereas binding of the inhibitor n-octylamine, a type II ligand, was not compromised. Binding of these ligands to P450 2B6 occurs in two phases. Stopped-flow spectral analysis of the binding kinetics of benzphetamine to PCP-inactivated 2B6 revealed a 15-fold decrease in the rate of binding during the second phase of the kinetics (k1 = 5.0 s–1, A1 = 30%; k2 = 0.02 s–1, A2 = 70%, where A2 indicates the fractional magnitude of the second phase) compared with the native enzyme (k1 = 8.0 s–1, A1 = 58%; k2 = 0.3 s–1, A2 = 42%). Analysis of benzphetamine metabolism by the inactivated protein using liquid chromatography/electrospray ionization/mass spectrometry showed that the rates of formation of nor-benzphetamine and hydroxylated nor-benzphetamine were decreased by 75 and 69%, respectively, whereas the rates of formation for amphetamine, hydroxybenzphetamine, and methamphetamine showed slight but statistically insignificant decreases after the inactivation. The rate of reduction of P450 2B6 by NADPH and reductase was decreased by 6-fold as a result of the modification by PCP. In addition, the extent of uncoupling of NADPH oxidation from product formation, a process leading to futile production of H2O2, increased significantly during the metabolism of ethylbenzene as a result of the inactivation.</description><subject>Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Benzphetamine - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Catalysis</subject><subject>Chromatography, Liquid</subject><subject>Cytochrome P-450 CYP2B6</subject><subject>Electron Transport</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Medical sciences</subject><subject>Oxidoreductases, N-Demethylating - antagonists & inhibitors</subject><subject>Oxidoreductases, N-Demethylating - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Phencyclidine - pharmacology</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><subject>Substrate Specificity</subject><issn>0090-9556</issn><issn>1521-009X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9v1DAQxSMEokvhyhH5wq1Z7MRxEg5I7WoLlYqoRCtxs8b_NkaJvbK9W-Vj8I3ralctHDjNyO83z6N5RfGe4CUhFf2kJrUkuFviijJGXhQL0lSkxLj_9bJY5ILLvmnYSfEmxt8YE0rr_nVxQvrctS1eFH--azmAszFZic4djHO0EXmD0qDRlQOZ7B6S9e7xbTUnL4fgJ41uaINRdcGQmNHNoJ2c5WiVdfozWhujZcomDv3ciZgCJI0urMvq5gytxyyGrN0GcNHocIbAKXTnpN9tx4y8LV4ZGKN-d6ynxd3l-nb1rbz-8fVqdX5dStq3qewaoVtZgwBhiKkxtLSvNK6BsI5JYKwVeY38RIRSAmrTMcZASEGN6kzb16fFl4PvdicmraR2edORb4OdIMzcg-X_Ks4OfOP3vGIdbmiVDZYHAxl8jEGbp1mC-WM4PIeT-44fwskDH_7-8Rk_ppGBj0cAooTR5AtJG5-4ilQdbSr6zA12M9zboPl2gDCB9KPfzLxuOeUtbTLXHTid77i3OvAobc5KqzwjE1fe_m_XB0oUu5E</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Shebley, Mohamad</creator><creator>Kent, Ute M.</creator><creator>Ballou, David P.</creator><creator>Hollenberg, Paul F.</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20090401</creationdate><title>Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling</title><author>Shebley, Mohamad ; Kent, Ute M. ; Ballou, David P. ; Hollenberg, Paul F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-85be7c3ababf1f30a7492e03a1686ca667bfec92e1bddba3f8666abcb4fd8f793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Benzphetamine - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Catalysis</topic><topic>Chromatography, Liquid</topic><topic>Cytochrome P-450 CYP2B6</topic><topic>Electron Transport</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Medical sciences</topic><topic>Oxidoreductases, N-Demethylating - antagonists & inhibitors</topic><topic>Oxidoreductases, N-Demethylating - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Phencyclidine - pharmacology</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><topic>Substrate Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shebley, Mohamad</creatorcontrib><creatorcontrib>Kent, Ute M.</creatorcontrib><creatorcontrib>Ballou, David P.</creatorcontrib><creatorcontrib>Hollenberg, Paul F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug metabolism and disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shebley, Mohamad</au><au>Kent, Ute M.</au><au>Ballou, David P.</au><au>Hollenberg, Paul F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling</atitle><jtitle>Drug metabolism and disposition</jtitle><addtitle>Drug Metab Dispos</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>37</volume><issue>4</issue><spage>745</spage><epage>752</epage><pages>745-752</pages><issn>0090-9556</issn><eissn>1521-009X</eissn><coden>DMDSAI</coden><abstract>Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was significantly affected as a result of the inactivation, whereas binding of the inhibitor n-octylamine, a type II ligand, was not compromised. Binding of these ligands to P450 2B6 occurs in two phases. Stopped-flow spectral analysis of the binding kinetics of benzphetamine to PCP-inactivated 2B6 revealed a 15-fold decrease in the rate of binding during the second phase of the kinetics (k1 = 5.0 s–1, A1 = 30%; k2 = 0.02 s–1, A2 = 70%, where A2 indicates the fractional magnitude of the second phase) compared with the native enzyme (k1 = 8.0 s–1, A1 = 58%; k2 = 0.3 s–1, A2 = 42%). Analysis of benzphetamine metabolism by the inactivated protein using liquid chromatography/electrospray ionization/mass spectrometry showed that the rates of formation of nor-benzphetamine and hydroxylated nor-benzphetamine were decreased by 75 and 69%, respectively, whereas the rates of formation for amphetamine, hydroxybenzphetamine, and methamphetamine showed slight but statistically insignificant decreases after the inactivation. The rate of reduction of P450 2B6 by NADPH and reductase was decreased by 6-fold as a result of the modification by PCP. In addition, the extent of uncoupling of NADPH oxidation from product formation, a process leading to futile production of H2O2, increased significantly during the metabolism of ethylbenzene as a result of the inactivation.</abstract><cop>Bethesda, MD</cop><pub>Elsevier Inc</pub><pmid>19144770</pmid><doi>10.1124/dmd.108.024661</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-9556 |
ispartof | Drug metabolism and disposition, 2009-04, Vol.37 (4), p.745-752 |
issn | 0090-9556 1521-009X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2680542 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors Aryl Hydrocarbon Hydroxylases - metabolism Benzphetamine - pharmacokinetics Biological and medical sciences Catalysis Chromatography, Liquid Cytochrome P-450 CYP2B6 Electron Transport Enzyme Inhibitors - pharmacology Medical sciences Oxidoreductases, N-Demethylating - antagonists & inhibitors Oxidoreductases, N-Demethylating - metabolism Pharmacology. Drug treatments Phencyclidine - pharmacology Spectrometry, Mass, Electrospray Ionization Substrate Specificity |
title | Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A04%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanistic%20Analysis%20of%20the%20Inactivation%20of%20Cytochrome%20P450%202B6%20by%20Phencyclidine:%20Effects%20on%20Substrate%20Binding,%20Electron%20Transfer,%20and%20Uncoupling&rft.jtitle=Drug%20metabolism%20and%20disposition&rft.au=Shebley,%20Mohamad&rft.date=2009-04-01&rft.volume=37&rft.issue=4&rft.spage=745&rft.epage=752&rft.pages=745-752&rft.issn=0090-9556&rft.eissn=1521-009X&rft.coden=DMDSAI&rft_id=info:doi/10.1124/dmd.108.024661&rft_dat=%3Celsevier_pubme%3ES009095562402004X%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19144770&rft_els_id=S009095562402004X&rfr_iscdi=true |